Intravenous immunoglobulin in symptomatic and asymptomatic children with perinatal HIV infection
L Olopoenia1, M Young, D White
1Department of Pediatrics, DC General Hospital, Washington, DC 20012, USA.
Insights
Intravenous immunoglobulin (IVIG) therapy reduced bacterial infections and improved growth in children with HIV. Symptomatic patients showed greater benefits from this immune support.
Area of Science:
- Pediatrics
- Immunology
- Infectious Diseases
Background:
- Children born to HIV-infected mothers are at risk for opportunistic infections.
- Assessing immune support strategies is crucial for managing pediatric HIV.
- Intravenous immunoglobulin (IVIG) is a potential therapeutic option.
Purpose of the Study:
- To evaluate the efficacy of monthly IVIG in reducing bacterial infections and improving growth in children with HIV.
- To compare outcomes between symptomatic, asymptomatic, and indeterminate HIV-infected children receiving IVIG.
Main Methods:
- A randomized study involving 135 infants born to HIV-infected mothers.
- Participants received monthly IVIG (200 mg/kg) for one year.
- Children were categorized into symptomatic (P2), asymptomatic (P1), and indeterminate (PO) groups based on infection evidence.
Main Results:
- A significant reduction in bacterial infections (otitis media, respiratory, urinary tract, gastroenteritis) was observed in symptomatic (P2) children compared to asymptomatic (P1) and control (PO) groups.
- Improved growth (weight and height > 50th percentile) was noted in the symptomatic group versus other groups.
- No significant difference in head circumference was found across the groups.
Conclusions:
- Monthly IVIG infusions appear beneficial for both symptomatic and asymptomatic HIV-infected children, reducing bacterial infection frequency.
- Symptomatic HIV-infected children demonstrated a more robust response to IVIG therapy compared to asymptomatic children.
- IVIG may enhance immune response and support growth in pediatric HIV patients.
Abstract:
One hundred thirty-five children born to human immunodeficiency virus (HIV)-infected mothers were selected randomly to receive immunoglobulin (Gamimune-N, Miles Pharmaceutical Co) 200 mg/kg monthly for 1 year. All patients were seropositive by ELISA and Western blot at birth. At the time of the study, 15 symptomatic (P2) and 57 asymptomatic (P1) patients with evidence of viral infection (positive HIV culture or P24 antigen) received the immunoglobulin. Sixty-three indeterminate (PO) patients with no evidence of infection served as the control. Mean age for infants in group P2 was 32 months, 26 months for group P1, and 11 months for group PO. Significant reduction in the frequency of bacterial infections (ie, otitis media, upper respiratory tract infections, urinary tract infections, and acute gastroenteritis) was seen in the symptomatic group compared with both the asymptomatic and the control groups. Growth as measured by weight and height > 50th percentile was also markedly better in the symptomatic group than either asymptomatic or control patients. There was no significant difference in head circumference in all three groups. These results indicate that monthly intravenous immunoglobulin infusion (IVIG) appears to be beneficial to both symptomatic and asymptomatic HIV patients in reducing the frequency of bacterial infection and also enhancement of the immune response. However, symptomatic patients responded much better than the asymptomatic patients.
More Related Videos
Related Concept Videos
Development of Immunocompetence
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
Immunodeficiency Diseases
There are three main causes of immunodeficiency disorders...
Poliomyelitis
Cytomegalovirus Disease
Respiratory Syncytial Virus Disease
Inhibitors of Virion Maturation and Assembly


